Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Indonesian Journal of Rheumatology
Rakhma Yanti Hellmi
Department of Internal Medicine, Faculty of Medicine, Diponegoro University
Medicine & Pharmacology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Intravenous Cyclophosphamide Infusion Effects on Skin Fibrosis, IL-6 and TGF-β1 Responses in Systemic Sclerosis with Interstitial Lung Disease Rakhma Yanti Hellmi; Harry Isbagio; Suharyo Hadisaputro
Indonesian Journal of Rheumatology Vol. 18 No. 1 (2026): IJR VOL 18 NO 1
Publisher : Indonesian Rheumatology Associantion

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.66446/IJR.v18i1.112

Abstract

Background: Systemic sclerosis (SSc) is a chronic multisystem disease characterized by organ fibrosis, microvascular damage, and immunological dysregulation. This study aimed to evaluate the effects of intravenous cyclophosphamide (CYC) infusion on skin fibrosis severity, interleukin-6 (IL-6), and transforming growth factor-beta 1 (TGF-β1) levels in patients with SSc-associated interstitial lung disease (SSc-ILD), compared to conventional disease-modifying antirheumatic drug (DMARD) therapy. Methods: This study included patients meeting the 2013 ACR/EULAR classification criteria for SSc. Thirty-two patients (47.8%) received intravenous CYC, while 35 patients (52.2%) received conventional DMARDs. Skin fibrosis severity, assessed by the modified Rodnan skin score (mRSS), alongside serum IL-6 and TGF-β1 levels, were measured at baseline and after six months of therapy. Efficacy was evaluated by comparing post-treatment values to baseline measurements. Results: Both CYC and conventional DMARDs significantly reduced mRSS and serum TGF-β1 levels post-therapy. When comparing the two groups, the reduction in IL-6 levels demonstrated a trend toward statistical significance (p=0.051). Conclusion: Intravenous CYC therapy substantially reduces skin fibrosis (mRSS) and serum TGF-β1 levels in patients with SSc-ILD.
Co-Authors Harry Isbagio Suharyo Hadisaputro